Internal Medicine, Endocrinology, Diabetes, & Metabolism · Rochester, NY
NPI
1376501494
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
2655 Ridgeway Ave, Suite 220
Rochester, NY, 14626
Phone (585) 368-4560
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,999
190 services
Medicare patients, 2024
147
Average age 72
Drug cost, 2024
$3.0M
6,159 prescriptions
Company payments, 2024
$115
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert Bingham was code 99214 (office e&m - established), 86 times for 69 patients. In total Robert Bingham billed 190 services in 6 codes, and Medicare paid $9,999.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-04-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 86 | 69 | $58.61 | $5,041 |
| 99213 Office E&M - Established | Office | 84 | 75 | $39.81 | $3,344 |
| 99222 Hospital E&M - Initial | Facility | 14 | 14 | $104.81 | $1,467 |
By year: 2022 $18K for 315 services; 2023 $17K for 289 services; 2024 $9,999 for 190 services.
Medicare prescription drug claims, 2024
In 2024, the drug Robert Bingham prescribed most often to Medicare patients was Lantus Solostar (Insulin Glargine,hum.Rec.Anlog), with 767 prescriptions and refills. In total Robert Bingham wrote 6,159 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 767 | 1,517 | 212 | $132K |
| Levothyroxine Sodium Generic | 546 | 1,382 | 156 | $8,487 |
| Ozempic Semaglutide | 341 | 452 | 71 | $426K |
| Trulicity Dulaglutide | 322 | 454 | 70 | $432K |
| Insulin Lispro Kwikpen U-100 Insulin Lispro | 301 | 499 | 93 | $105K |
| Jardiance Empagliflozin | 232 | 456 | 57 | $263K |
| Humalog Kwikpen U-100 Insulin Lispro | 200 | 378 | 66 | $90K |
| Tresiba Flextouch U-100 Insulin Degludec | 172 | 263 | 31 | $139K |
| Metformin Hcl Generic | 170 | 497 | 62 | $2,189 |
| Metformin Hcl Er Metformin Hcl | 170 | 405 | 53 | $2,647 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 164 | 379 | 64 | $18K |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 154 | 371 | 60 | $16K |
| Novolog Flexpen Insulin Aspart | 144 | 231 | 35 | $50K |
| Glimepiride Generic | 139 | 397 | 49 | $1,837 |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 127 | 217 | 31 | $66K |
Brand drugs: 3,755 claims; generic drugs: 1,624 claims.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Robert Bingham $115 ($115 in general payments such as food, travel and fees) from 1 company. The largest payer was Amgen Inc. with $115.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 1 | $115 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.